Goldman Sachs is out with its report today on HCA HCA, downgrading HCA from Buy to Neutral.
In a note to clients, Goldman Sachs writes, "We downgrade HCA to Neutral from Buy as we now model lower revenue and EPS for 2011-13. We have also lowered our price target to $31 from $40. Our bullish thesis on HCA reflected our view that the company could out-execute its peers and meet or exceed our/Street targets despite headwinds from weak volume trends and reimbursement pressures. While HCA stock sold off (-19% today vs. SP500 -0.6%), more than the 2Q miss (-5% on EBITDA, -14% on EPS) would imply, the weaker-than-expected results come just four months after the IPO and we think will cost HCA credibility among investors that will take substantial time to re-build (in particular, the hoped-for ‘beat and raise' element of the story)."
At the time of posting, shares of HCA were trading at $27.25, down 2.57% from Monday's close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in